Detalhe da pesquisa
1.
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.
Cell
; 180(5): 895-914.e27, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32142680
2.
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.
Immunity
; 47(4): 789-802.e9, 2017 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045907
3.
HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors.
Virol J
; 21(1): 14, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38200531
4.
Tumor intrinsic and extrinsic immune functions of CD155.
Semin Cancer Biol
; 65: 189-196, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31883911
5.
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
Semin Cancer Biol
; 48: 91-103, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28467889
6.
The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer.
Cancer Cell Int
; 16: 24, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27034617
7.
Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease.
Lancet Microbe
; 5(4): e400-e408, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246188
8.
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma.
Lancet Haematol
; 10(7): e539-e548, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407143
9.
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
Front Immunol
; 13: 976968, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36119058
10.
Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)?
Front Microbiol
; 12: 724654, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34408742
11.
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Clin Cancer Res
; 26(14): 3671-3681, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32345648
12.
Cancer immunoediting and resistance to T cell-based immunotherapy.
Nat Rev Clin Oncol
; 16(3): 151-167, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30523282
13.
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
Clin Cancer Res
; 25(19): 5743-5751, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31040150
14.
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.
Oncoimmunology
; 8(5): e1581530, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31069141
15.
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.
Oncoimmunology
; 8(2): e1546068, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713806
16.
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Oncoimmunology
; 7(6): e1431088, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29872559
17.
Resistance to PD1/PDL1 checkpoint inhibition.
Cancer Treat Rev
; 52: 71-81, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27951441
18.
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Genome Med
; 8(1): 111, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27782862
19.
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Cancer Discov
; 6(12): 1382-1399, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663893
20.
PD1 functions by inhibiting CD28-mediated co-stimulation.
Clin Transl Immunology
; 6(5): e138, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28690844